2007-05-01
Plasma β amyloid and impaired CO2-induced cerebral vasomotor reactivity
Publication
Publication
Neurobiology of Aging: age-related phenomena, neurodegeneration and neuropathology , Volume 28 - Issue 5 p. 707- 712
Amyloid β (Aβ) may disturb cerebral autoregulation by damaging the wall of small cerebral blood vessels and by direct negative vasoactive properties. We assessed whether previous and concurrent plasma Aβ1-40and Aβ1-42levels were associated with an impaired CO2-induced cerebral vasomotor response. In the longitudinal population-based Rotterdam Study we measured plasma Aβ levels and cerebral vasomotor reactivity to hypercapnia with transcranial Doppler ultrasonography (TCD) in 441 people, aged 60-90 years. We performed age and sex adjusted logistic regression analysis. Plasma Aβ levels assessed on average 6.5-year before TCD were linearly associated with an impaired CO2-induced cerebral vasomotor response (odds ratio 1.48 (95%CI 1.19;1.84) per standard deviation increase in Aβ1-40, and 1.36 (95%CI 1.09;1.70) per standard deviation increase in Aβ1-42). Such an association was not present for Aβ assessed concurrently with the TCD measurement. Persons whose plasma Aβ1-40levels had decreased in the 6.5-year period preceding TCD measurements were more likely to have an impaired CO2-induced vasomotor reactivity. Overall our observations are most compatible with plasma Aβ levels representing vascular Aβ deposits years later resulting in impaired CO2-induced vasomotor reactivity.
Additional Metadata | |
---|---|
, , , , , | |
doi.org/10.1016/j.neurobiolaging.2006.03.011, hdl.handle.net/1765/35805 | |
Neurobiology of Aging: age-related phenomena, neurodegeneration and neuropathology | |
Organisation | Erasmus MC: University Medical Center Rotterdam |
van Dijk, E., Prins, N., Hofman, A., Tikka-Kleemola, P., Koudstaal, P., & Breteler, M. (2007). Plasma β amyloid and impaired CO2-induced cerebral vasomotor reactivity. Neurobiology of Aging: age-related phenomena, neurodegeneration and neuropathology, 28(5), 707–712. doi:10.1016/j.neurobiolaging.2006.03.011 |